S&P 500 slips on report Fed’s Waller leading race to replace Powell; tech shines
Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics (NASDAQ:NKTR), recently sold 10,300 shares of the company’s common stock. The transactions occurred on February 19, 2025, with prices ranging from $1.00 to $1.04 per share, resulting in a total sale value of approximately $10,403. Following this sale, Zalevsky retains ownership of 316,604 shares in the company.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) and was not a discretionary trade by Zalevsky. This information highlights the ongoing financial activities of executives at Nektar Therapeutics, a company based in San Francisco, California, and engaged in pharmaceutical preparations.
In other recent news, Nektar Therapeutics announced that its drug candidate, rezpegaldesleukin, received Fast Track designation from the FDA for treating moderate-to-severe atopic dermatitis in patients aged 12 and older. This designation aims to expedite the drug’s development and review process. The company has also reached its enrollment target for the Phase 2b REZOLVE-AD trial, which involves 398 patients and focuses on the drug’s efficacy in treating atopic dermatitis. The trial’s primary measure is the improvement in Eczema Area and Severity Index (EASI) scores after a 16-week treatment period.
Additionally, Nektar disclosed a significant leadership change, with Mary Tagliaferri stepping down as Chief Medical (TASE:BLWV) Officer and Brian Kotzin stepping in as the interim replacement. B.Riley has initiated coverage on Nektar with a Buy rating, citing the potential of REZPEG to disrupt the atopic dermatitis market. The firm noted that REZPEG’s development could challenge the dominance of Sanofi (NASDAQ:SNY)’s Dupixent in this market. Piper Sandler’s recent report also highlighted Nektar Therapeutics as one of the companies with key Phase 2b readouts expected in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.